
August 9, 2023

MDNA11 IL-2 Super Agonist

ABILITY trial update call

Fahar Merchant, PhD Arash Yavari, MBBS, DPhil





Forward-Looking Statement and Cautionary Language

This presentation (the "Presentation") contains information about Medicenna Therapeutics Corp. ("Medicenna" or the "Company"), current as at the date hereof or as at such earlier date as may be specified herein. This Presentation does not constitute or form part of, and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of Medicenna or any of its subsidiaries or any other person in any jurisdiction or an inducement to enter into investment activity and does not constitute marketing material in connection with any such securities, and there is no current offering or soliciting for the sale of securities in any jurisdiction.

This Presentation and the information contained herein is for information purposes only, may not be reproduced or distributed to others, at any time, in whole or in part, for any purpose, and may not be used for any other purpose, without the prior written consent of Medicenna, and all recipients agree that they will use this Presentation solely for information purposes. Acceptance of this Presentation by any person constitutes an agreement to be bound by the terms of this disclaimer.

This Presentation contains forward-looking statements within the meaning of applicable securities laws that relate to the future operations of the Company, plans and projections and other statements, including statements on the development potential and milestones of MDNA11. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expect", "believe", "seek", "potentially" and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the latest Annual Information Form and Annual Report on Form 20-F of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada and the United States.

Assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. Undue reliance should not be placed on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this Presentation are expressly qualified by this cautionary statement. The forward-looking statements contained as of the date hereof and except as required by law, the Company does not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.

Speaker & Agenda

Arash Yavari, MBBS, DPhil

Dr. Arash Yavari is a physician-scientist with over 20 years of broad clinical, scientific and industry drug development experience. He has extensive expertise in early clinical development and scientific strategy across a range of therapeutic areas, including immuno-oncology, hemato-oncology, inflammation, autoimmunity, cardiometabolic and rare disease.


Dr. Yavari holds a Bachelor of Science, and Bachelor of Medicine, Bachelor of Surgery (MBBS) from the University of London, a Doctorate (DPhil) from the University of Oxford and is on the General Medical Council (GMC) Specialist Register. He is a Member of the Royal College of Physicians (MRCP) of the United Kingdom and a Member of the Faculty of Pharmaceutical Medicine (MFPM).



Agenda

- Introduction
- ABILITY Study Clinical Update
- Next Milestones & Conclusion
- Questions & Answers

MDNA11: Long-acting IL-2 Superkine Engineered for Optimized Efficacy



Designed to overcome key limitations of IL-2 for cancer immunotherapy

+


Potentiates activation of anti-cancer immune cells (CD8⁺ T & NK)

Non-α binder

Reduces stimulation of procancer immune cells (Tregs)

Optimized anti-cancer response =


- Fusion to human albumin overcomes the very short half-life of IL-2 and the need for frequent patient dosing: MDNA11 can be given every 2 weeks vs. IL-2 given 3x/day for 5 days
- Albumin fusion also promotes durable MDNA11 accumulation at tumor sites to potentially further enhance efficacy



MDNA11, IL-2 Superkine with Single Agent Clinical Activity

Not Alpha, Beta-Enhanced	 Differentiated next-generation IL-2: engineered as a long-acting, enhanced potentiator of CD8⁺
IL-2 Super Agonist	effector T cells and NK cells with limited Treg cell expansion compared to native IL-2
Albumin-Extended Half-Life	 Albumin scaffold extends half-life via FcRn recycling, lowers kidney clearance, and enhances homing
and Tumor-Homing	to tumor sites and draining lymph nodes
Desirable Safety Profile in Clinic	 Well-tolerated safety profile with majority of AEs transient and low-grade (1-2). No dose-limiting toxicity or vascular leak syndrome observed
Single Agent Activity in	 Promising clinical activity with deep and durable responses observed during monotherapy dose escalation
Ongoing Phase 1/2 Study	in patients with treatment-refractory solid tumors and progression on IO
Combination with Checkpoint	 Strong memory response as a single or combination IO agent. Desirable safety and PK characteristics
Inhibitors and Beyond	allows more combination strategies.

ABILITY STUDY - Clinical Update Arash Yavari, MBBS, DPhil






ABILITY: Phase 1/2 Dose Escalation & Expansion Study

Monotherapy Dose Escalation

N = 20 patients with advanced, treatment-refractory solid tumors MDNA11 Q2W IV; cut-off date: June 20, 2023

Modified 3+3 design. Open-label Assess safety & tolerability of MDNA11 monotherapy Identify Recommended Dose for Expansion (RDE) <u>NCT05086692</u>



MDNA11 Monotherapy Dose Expansion

N≈40: Melanoma and other selected solid tumors

MDNA11 Q2W IV at RDE

Further evaluate safety and tolerability

Evaluate single-agent anti-tumor activity

MDNA11 + Anti-PD-1 (Pembrolizumab) Dose Expansion

N≈40: Melanoma and other selected solid tumors

MDNA11 + anti-PD-1 (pembrolizumab)

Evaluate safety and tolerability of MDNA11 / anti-PD-1 combination

Evaluate combination anti-tumor activity



ABILITY: Patient Baseline Characteristics in Dose Escalation

Demographics/Performance	
Median age, years (range)	61 (27-78)
Male (%)	16/20 (80%)
ECOG 0	14/20 (70%)
ECOG 1	6/20 (30%)


Prior Systemic Therapies	
Prior Lines of Therapy: 1	5/20 (25%)
Prior Lines of Therapy: 2-4	15/20 (75%)
Prior Immunotherapy	15/20 (75%)
Prior Targeted Therapy	5/20 (25%)
Prior Chemotherapy	9/20 (45%)

11/20 (55%)
2/20 (10%)
2/20 (10%)
2/20 (10%)
1/20 (5%)
1/20 (5%)
1/20 (5%)


Most patients received multiple prior lines of anti-cancer therapy, including immunotherapy



Single Agent Safety Profile Across all Dose Escalation Cohorts



MDNA11-Induced Sustained Lymphocyte Expansion




Medicenna Therapeutics 2023 MDNA11 Clinical Update


 \otimes

No Significant Eosinophilia (Associated with VLS)

Vascular Leak Syndrome (VLS) is a hallmark dose-limiting toxicity of IL-2





MDNA11 Preferentially Induced CD8⁺ T Cell Expansion Over Tregs



CD8⁺ T cells are powerful effectors of the anti-cancer immune response

MDNA11 Boosts Population of Potent CD8⁺T Cells But Not Tregs






Increased co-stimulation (ICOS⁺)

of CD8⁺ T cells (peak @ 90 µg/kg)


Limits expansion of highly suppressive ICOS⁺ Tregs




Peak fold-change relative to baseline. Target dose data are shown

MDNA11 Expands Potent CD8⁺ T Cells But Weaker Tregs

OX40 promotes CD8+ T cell survival & expansion (peak @ 90 μg/kg)



Enhances OX40 in Tregs making them less immunosuppressive (Peak at 90 µg/kg)




Peak fold-change relative to baseline. Target dose data are shown


Medicenna Therapeutics |2023| MDNA11 Clinical Update 14

Durable Responses Observed During Dose Escalation

SD lasting ~18 months in 71-year-old patient with metastatic melanoma treated with 2 prior lines of IO



MDNA11 Shows Single Agent Clinical Activity






Confirmed partial response (PR) achieved in a 55-year-old patient with metastatic pancreatic cancer treated with MDNA11 at 60 μ g/kg IV Q2W

19 of 20 patients with at least one follow-up assessment

Data cut-off: June 20, 2023

Pancreatic Cancer – Durable Partial Response to Single-Agent MDNA11




- Patient with pancreatic ductal adenocarcinoma (PDAC)
- Surgical resection (Whipple's procedure) June 2021
- Adjuvant FOLFIRINOX: Progression
- Abraxane + gemcitabine: Discontinued due to Toxicity
- Pembrolizumab: Progression
- Deepening shrinkage of target lesions on MDNA11
- Complete regression of one target & one non-target lesion

Patient continues on single agent MDNA11 at 60 μg/kg Q2W


ABILITY Study Plan – Dose Expansion & Combination Phase

Global, multi-center, open-label Phase 1/2 study

Monotherapy dose escalation and expansion; combination with Pembrolizumab



Conclusion Fahar Merchant, PhD CEO of Medicenna Therapeutics






Upcoming Anticipated Milestones & Financial Summary

ABILITY Study Fully Funded – Cash Runway Through Q3 2024

Anticipated Miles	tones
Start of ABILITY monotherapy expansion	Q3 2023
Update from ABILITY monotherapy expansion	Q4 2023
Commence combination phase of ABILITY with MDNA11 & pembrolizumab	Q4 2023
Update from ABILITY mono- and combination phases	Q1 2024

Financial Highlights			
Nasdaq/TSX	MDNA		
Headquarters	Toronto, CA		
Cash	CDN \$29.6M [*]		
Debt	\$0		
referred Shares	None		
ssued and Outstanding	~70 Million*		
Fully Diluted	~92 Million*		

* As of June 30, 2023.



Thank you

